The Insud Pharmaceuticals division is launching its generics of Alkeran and Prometrium, which had market sizes of $20.4 million and $74.8 million for the year ended December 2020, according to IQVIA data.
ANI's acquisition of New Jersey-based Novitium for $163.5 million will strengthen its generics business and diversify its portfolio, according to the company.
With tentative approval from the Food and Drug Administration, Viatris faces a legal battle to bring the generic to market and has not planned for any revenue from the product for 2021.
The Afinitor brand and its generic versions had a market value of $712 million, while Saphris had a market value of $233 million, during the 12 months ended December 2020.
Mayne Pharma launched four generic contraceptive products this year. They have a combined market value of approximately $315 million for the 12 months ended January 2021, according to IQVIA.